{"id":"NCT00764868","sponsor":"Shire","briefTitle":"Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study","officialTitle":"A Phase III, Open-Label, Extension, Multi-Center, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11-13","primaryCompletion":"2010-04-22","completion":"2010-04-22","firstPosted":"2008-10-02","resultsPosted":"2011-03-28","lastUpdate":"2021-06-14"},"enrollment":269,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["ADHD"],"interventions":[{"type":"DRUG","name":"Lisdexamfetamine Dimesylate (LDX)","otherNames":["Vyvanse"]}],"arms":[{"label":"LDX","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the long-term safety of LDX administered as a daily morning dose (30, 50, and 70 mg/day) in the treatment of adolescents (13-17 years of age inclusive at the time of consent).","primaryOutcome":{"measure":"Change From Baseline (From the Antecedent Study, SPD489-305) in the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at up to 52 Weeks","timeFrame":"Baseline and up to 52 weeks","effectByArm":[{"arm":"Lisdexamfetamine Dimesylate (LDX)","deltaMin":-26.2,"sd":9.75}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":45,"countries":["United States"]},"refs":{"pmids":["23410138"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":265},"commonTop":["Upper Respiratory Tract Infection","Decreased Appetite","Headache","Weight Decreased","Irritability"]}}